Cargando…

Other Angiotensins

Besides the major role of angiotensin II (Ang II) in the renin-angiotensin system (RAS), other angiotensin peptides with different lengths were recently discovered to be biologically active and they possess individual receptors and signaling pathways. Ang III stimulates AT1 and AT2 receptors and its...

Descripción completa

Detalles Bibliográficos
Autor principal:	Wong, Marty K.S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149573/ http://dx.doi.org/10.1016/B978-0-12-801028-0.00178-1

Ejemplares similares

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Angiotensin converting enzyme
por: Wong, Marty Kwok-Shing
Publicado: (2021)

The Renin-Angiotensin-Aldosterone System in Metabolic Diseases and Other Pathologies
por: Ortiz, Rudy M., et al.
Publicado: (2023)

Differential clinical profile of candesartan compared to other angiotensin receptor blockers
por: Cernes, Relu, et al.
Publicado: (2011)

Relationship Between ACE2 and Other Components of the Renin-Angiotensin System
por: Cohen, Jordana B., et al.
Publicado: (2020)

Comparisons of Staphylococcus aureus infection and other outcomes between users of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers: lessons for COVID-19 from a nationwide cohort study
por: Bidulka, Patrick, et al.
Publicado: (2020)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
por: Wong, Martin C.S., et al.
Publicado: (2020)

Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19
por: Rizk, John G., et al.
Publicado: (2021)

Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy()
por: Ono, Takashi, et al.
Publicado: (2013)

A Comparison of Disease Severity and Outcomes in COVID-19 Cases Taking Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Versus Other Antihypertensive Drugs
por: Abdullah, Muhammad, et al.
Publicado: (2021)

The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man
por: Alessandra, Del Fiorentino, et al.
Publicado: (2009)

Management of renin-angiotensin-aldosterone inhibitors and other antihypertensives and their clinical effects on pre-anesthesia blood pressure
por: Balcı, Eda, et al.
Publicado: (2022)

Loss of Angiotensin-Converting Enzyme-2 Leads to the Late Development of Angiotensin II-Dependent Glomerulosclerosis
por: Oudit, Gavin Y., et al.
Publicado: (2006)

Angiotensin-(1-7), Angiotensin-Converting Enzyme 2, and New Components of the Renin Angiotensin System
por: Trask, Aaron J., et al.
Publicado: (2009)

Genetic Evidence for Protective Effects of Angiotensin-Converting Enzyme Against Alzheimer Disease But Not Other Neurodegenerative Diseases in European Populations
por: Ryan, David K., et al.
Publicado: (2022)

Newer Insights into the Biochemical Physiology of the Renin–Angiotensin System: Role of Angiotensin-(1-7), Angiotensin Converting Enzyme 2, and Angiotensin-(1-12)
por: Ferrario, Carlos M., et al.
Publicado: (2009)

Modulation of angiotensin II signaling in the prevention of fibrosis
por: Murphy, Amanda M, et al.
Publicado: (2015)

Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach
por: Nixon, R M, et al.
Publicado: (2009)

Neuronal Angiotensin
por: Allen, A.M., et al.
Publicado: (2009)

Thermo-, Radio- and Photostability of Perindopril Tert-butyloamine in The Solid State. Comparison to Other Angiotensin Converting Enzyme Inhibitors
por: Wzgarda, Anna, et al.
Publicado: (2017)

Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective
por: Kim, Hee-Sung, et al.
Publicado: (2021)

Comparison of renin–angiotensin–aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes
por: Bezabih, Yihienew M., et al.
Publicado: (2021)

Angiotensin II Type 1 Receptor Antibodies Are Higher in Lupus Nephritis and Vasculitis than Other Glomerulonephritis Patients
por: Szymczak, Maciej, et al.
Publicado: (2022)

Retinal angiotensin II and angiotensin-(1-7) response to hyperglycemia and an intervention with captopril
por: Senanayake, Preenie deS, et al.
Publicado: (2018)

Regulation of Cardiovascular Control Mechanisms by Angiotensin-(1–7) and Angiotensin-Converting Enzyme 2
por: Ferrario, Carlos M., et al.
Publicado: (2010)

Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
por: Kim, Jihoon, et al.
Publicado: (2023)

RENAL HYPERTENSION IN RATS IMMUNIZED AGAINST ANGIOTENSIN I AND ANGIOTENSIN II
por: Oates, Helen F., et al.
Publicado: (1974)

The Role of Angiotensin II in Poisoning-Induced Shock—a Review
por: Chen, Andrew, et al.
Publicado: (2022)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

New angiotensins
por: Varagic, Jasmina, et al.
Publicado: (2008)

Cognitive enhancing effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on learning and memory
por: Nade, V. S., et al.
Publicado: (2015)

Distinct Molecular Effects of Angiotensin II and Angiotensin III in Rat Astrocytes
por: Clark, Michelle A., et al.
Publicado: (2013)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all‐cause mortality and other clinical outcomes in patients with confirmed COVID‐19: A systemic review and meta‐analysis
por: Jia, Na, et al.
Publicado: (2021)

Genomic and evolutionary comparison between SARS-CoV-2 and other human coronaviruses
por: Chen, Zigui, et al.
Publicado: (2021)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

Angiotensin II Peptides
por: Izumi, Yasukatsu, et al.
Publicado: (2013)

Receptors | Angiotensin Receptors
por: Pardhi, Triveni R., et al.
Publicado: (2021)

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
por: Bellomo, Rinaldo, et al.
Publicado: (2020)

Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
por: Jiang, Fan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_k9fq3mu8ggjbuu6svi44n3c7jk